Harbour BioMed

Harbour BioMed is one of the Best Biotech Companies in China. Itdescribes itself as a global biopharmaceutical enterprise. It's true that labeling Harbour as a Chinese corporation can be difficult; its website isn't even in Chinese, and its news releases these days begin with three cities in the dateline—Cambridge, Massachusetts, Rotterdam, the Netherlands, and Suzhou, China.

Harbour's research interests are on oncology and immunology. While the business is developing novel compounds from the ground up, HanAll Biopharma licensed its two lead programs, anti-FcRn antibody batoclimab and TNF-alpha inhibitor tanfanercept. Harbour is putting batoclimab through its paces in a variety of conditions, including NMOSD, myasthenia gravis, and immune thrombocytopenia. According to the company's application (PDF) to HKEX, the medicine will be submitted for Chinese approval in NMOSD and MG in 2022.

Harbour gained ex-China rights to a PD-L1 antibody in a 2018 arrangement with China's Kelun Biotech. However, the medicine vanished from the company's "Core Product" list, as mentioned in its Hong Kong IPO application. According to the paper, Harbour received FDA approval in September 2019 to begin a phase 2 trial of the drug in nasopharyngeal cancer.

Headquarters: 2F, Tower A, 420 Fenglin Road, Xuhui District, Shanghai

CEO: Jingsong Wang

Founded: 2016

Website: https://www.harbourbiomed.com/